It is related in structure to 5-Methoxy-N,N-diisopropylbenzofuranethylamine.
This compound has little to no history of human usage prior to its September 2015 release on the online research chemical market.
Very little is known about the pharmacological properties, metabolism, and toxicity of 5-MeO-DiBF.
Due to its extreme novelty and unknown toxicity profile, it is highly advised that one use harm reduction practices if using this substance.
5-Meo-DIBF, or 5-methoxy-N,N-diisopropylbenzofuranethylamine, is a synthetic heterocyclic alkaloid molecule of the benzofuran class.
Benzofuran is a bicyclic structure formed by the fusion of a benzene ring and a furan ring, a five member aromatic ring containing an oxygen substituent.
5-Meo-DIBF is composed of a benzofuran group attached at R3 to an amino group via an ethyl side chain.
It is substituted at R5 of the benzofuran heterocycle with a methoxy (MeO) functional group CH3O−; it also contains two isopropyl chains bound to the terminal amine RN of its tryptamine backbone (DiBF).
The benzofuran group of is closely related in structure to the indole found in tryptamines; benzofuran contains an oxygen group at the same location that indole contains a nitrogen.
As such, 5-MeO-DiBF is closely related in structure to the psychedelic tryptamine 5-Methoxy-N,N-diisopropylbenzofuranethylamine. 5-MeO-DiBF is the benzofuran analogue of .
5-MeO-DiBF likely acts as a 5-HT2A partial agonist.
The psychedelic effects are believed to come from its efficacy at the 5-Methoxy-N,N-diisopropylbenzofuranethylamine and 5-HT2 family of serotonin receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
This compound is several times less potent as a serotonin agonist than 5-MeO-DiPT.
It has relatively more activity at 5-HT1A, but still shows strongest effects at the 5-HT2 family of receptors